Περίληψη:
Interleukin-1 beta (IL1 beta) is primarily produced by monocytes in the
periphery and the brain. Yet, IL1 beta protein levels have to date been
investigated in major depressive disorder (MDD) and antidepressant
response using either plasma or serum assays although with contradictory
results, while mononuclear cell assays are lacking despite their
extensive use in other contexts. In this pilot study, we comparatively
assessed IL1 beta in mononuclear lysates and plasma in depressed MDD
patients over treatment and healthy controls (HC). We recruited 31
consecutive adult MDD inpatients and 25 HC matched on age, sex, and BMI.
Twenty-six patients completed an 8-week follow-up under treatment. IL1
beta was measured in both lysates and plasma in patients at baseline
(T0) and at study end (T1) as well as in HC. We calculated Delta IL1
beta(%) for both lysates and plasma as IL1 beta percent changes from T0
to T1. Seventeen patients (65.4% of completers) were responders at T1
and had lower baseline BMI than non-responders (p = 0.029). Baseline IL1
beta from either plasma or lysates could not efficiently discriminate
between depressed patients and HC, or between responders and
non-responders. However, the two response groups displayed contrasting
IL1 beta trajectories in lysates but not in plasma assays (response
group by time interactions, p = 0.005 and 0.96, respectively). Delta IL1
beta(%) in lysates predicted response (p = 0.025, AUC = 0.81; accuracy
= 84.6%) outperforming Delta IL1 beta(%) in plasma (p = 0.77,
AUC=0.52) and was robust to adjusting for BMI. In conclusion, Delta IL1
beta(%) in mononuclear lysates may be a longitudinal biomarker of
antidepressant response, potentially helpful in avoiding untimely
switching of antidepressants, thereby warranting further investigation.
Συγγραφείς:
Ferentinos, Panagiotis
Maratou, Eirini
Antoniou, Anastasia and
Serretti, Alessandro
Smyrnis, Nikolaos
Moutsatsou, Paraskevi
